TG Therapeutics' Subcutaneous BRIUMVI Shows Promising Phase 1 Results, Expanding Market Potential — TG Therapeutics, Inc.

Event summary

TG Therapeutics reported positive Phase 1 trial results for a subcutaneous formulation of BRIUMVI, showing over 60% bioavailability compared to IV administration.
The Phase 3 trial, evaluating quarterly and every-other-month dosing regimens, is fully enrolled with topline data expected by early 2027.
Subcutaneous BRIUMVI demonstrated non-inferior drug exposure and a favorable safety profile, supporting potential at-home self-administration.
If approved, the subcutaneous formulation could nearly double the addressable market for BRIUMVI by enabling self-administered, quarterly anti-CD20 therapy.

The big picture

TG Therapeutics' success in developing a subcutaneous formulation of BRIUMVI aligns with broader industry trends toward patient-friendly drug delivery systems. The potential to reduce the number of injections per year could enhance compliance and expand the drug's reach in the relapsing multiple sclerosis (RMS) market. The strategic shift toward self-administered therapies reflects a growing emphasis on convenience and accessibility in chronic disease management.

What we're watching

Regulatory Approval: Whether the Phase 3 trial results will support FDA approval for the subcutaneous formulation by 2028.
Market Adoption: The pace at which healthcare providers and patients will transition to the subcutaneous version if approved.
Competitive Dynamics: How TG Therapeutics will position BRIUMVI against existing and emerging anti-CD20 therapies in the multiple sclerosis market.